4.6 Article

Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study

Journal

ALZHEIMERS RESEARCH & THERAPY
Volume 13, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13195-020-00765-5

Keywords

Alzheimer's; Tau; Amyloid; Imaging; Longitudinal; Autosomal-Dominant

Funding

  1. NIH Office of the Director [DP5OD019833]
  2. National Institute on Aging [R01AG054671, R01 AG031581, P30 AG19610]
  3. Alzheimer's Association
  4. Massachusetts General Hospital ECOR [1200228010, 1200-228767]
  5. Anonymous Foundation
  6. Administrative Department of Science, Technology and Innovation (Colciencias Colombia) [111565741185]
  7. NIH-NIA [R01AG062559, K23 AG058805-01]
  8. NIH-NIA National Research Service Award [1F31AG062158-01A1]
  9. Alzheimer's Association Clinical Fellowship [AACF_16-440965]
  10. Massachusetts General Hospital Rappaport Fellowship
  11. Banner Alzheimer's Foundation
  12. NOMIS Foundation
  13. NIH [P01AG036694, P50AG005134, U19 AG10483, R01 AG027435, P50 AG00513421, AG036694, R01 AG046396, R13 AG042201174210, U19AG10483, U01AG024904]
  14. Eli Lilly
  15. NIH-Lilly [U19AG10483]
  16. Marr Foundation

Ask authors/readers for more resources

In ADAD, there are different rates of tau accumulation in various brain regions, with the fastest accumulation in the parietal neocortex. The baseline EC tau PET signal is a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers.
Background: Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization of the trajectories of cerebral amyloid-beta (A beta) and tau accumulation in the decades prior to clinical symptom onset. Longitudinal rates of regional tau accumulation measured with positron emission tomography (PET) and their relationship with other biomarker and cognitive changes remain to be fully characterized in ADAD. Methods: Fourteen ADAD mutation carriers (Presenilin-1 E280A) and 15 age-matched non-carriers from the Colombian kindred underwent 2-3 sessions of A beta (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET, structural magnetic resonance imaging, and neuropsychological evaluation over a 2-4-year follow-up period. Annualized rates of change for imaging and cognitive variables were compared between carriers and non-carriers, and relationships among baseline measurements and rates of change were assessed within carriers. Results: Longitudinal measurements were consistent with a sequence of ADAD-related changes beginning with A beta accumulation (16 years prior to expected symptom onset, EYO), followed by entorhinal cortex (EC) tau (9 EYO), neocortical tau (6 EYO), hippocampal atrophy (6 EYO), and cognitive decline (4 EYO). Rates of tau accumulation among carriers were most rapid in parietal neocortex (similar to 9%/year). EC tau PET signal at baseline was a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers. Conclusions: Our results are consistent with the sequence of biological changes in ADAD implied by cross-sectional studies and highlight the importance of EC tau as an early biomarker and a potential link between A beta burden and neocortical tau accumulation in ADAD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available